Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Women may have better verbal memory skills than men during early stages of Alzheimer's disease

Women may have better verbal memory skills than men even when their brains show the same level of problems metabolizing glucose, which occurs in people with Alzheimer's disease, according to research published in the October 5, 2016, online issue of Neurology®, the medical journal of the American Academy of Neurology.

5 Oct 2016

Novel bifunctional dimers show promise in preventing Parkinson's disease

A team of researchers from the University of Saskatchewan has developed two caffeine-based chemical compounds that show promise in preventing the ravages of Parkinson's disease.

30 Sep 2016

Professor David Goldstein appointed as chief adviser for AstraZeneca’s genomics initiative

AstraZeneca today announced that Professor David Goldstein will join the Company in the consultative role of Chief Adviser, Genomics to lead its integrated genomics initiative, which was announced in April.

30 Sep 2016

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer's disease.

30 Sep 2016

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

The Alzheimer's Drug Discovery Foundation announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna for use as a cancer therapy) in patients with Alzheimer's disease.

29 Sep 2016

Experimental PET tracer can diagnose concussion-related brain degeneration in living person

An experimental positron emission tomography (PET) tracer can effectively diagnose concussion-related brain degeneration while a person is still alive, according to a proof-of-concept study conducted at the Icahn School of Medicine at Mount Sinai and published September 27 in the journal Translational Psychiatry.

27 Sep 2016

EVG brings high-volume manufacturing process solutions to biotechnology and medical device market

EV Group, a leading supplier of wafer bonding and lithography equipment for the MEMS, nanotechnology and semiconductor markets, today announced that it is increasing its focus on bringing its high-volume manufacturing process solutions and services to the biotechnology and medical device market.

27 Sep 2016

Magnetic bacteria can be promising vehicle for efficiently delivering tumor-fighting drugs

Researchers funded in part by the National Institute of Biomedical Imaging and Bioengineering have recently shown that magnetic bacteria are a promising vehicle for more efficiently delivering tumor-fighting drugs. They reported their results in the August 2016 issue of Nature Nanotechnology.

23 Sep 2016

Virginia Tech researchers identify novel compound that blocks growth of deadly fungus

Researchers with the Virginia Tech Center for Drug Discovery have identified a compound that blocks the growth of a fungus that causes deadly lung infections and allergic reactions in people with compromised immune systems.

22 Sep 2016

Experts receive $5.2 million NIH grant to develop affordable test for diagnosing Chagas disease

An international team of researchers led by infectious disease experts at the University of Georgia has received $5.2 million from the National Institutes of Health to develop a more accurate, affordable diagnostic test for Chagas disease, a parasitic infection that kills more than 50,000 people each year in Central and South America.

21 Sep 2016

Crick researchers find promising target for new tuberculosis drugs

Scientists led by Dr Luiz Pedro Carvalho at the Francis Crick Institute in London have found a promising new target in the search for new tuberculosis drugs. In the process, they say they've proven the strengths of a new research technique called metabolomics.

20 Sep 2016

Human pluripotent stem cells may revolutionize drug discovery in heart disease

Coaxing stem cells from patients to become heart cells may help clinicians personalize drug treatments and prevent heart-related toxicity.

20 Sep 2016

Open-source research mechanism could lead to discovery of new, cheap medicines for malaria

Malaria is one of the leading causes of mortality in developing countries – last year killing more than 400,000 people. Researchers worldwide have found the solution for drug discovery could lie in open, “crowd-sourced” science.

16 Sep 2016

Unique open science project shows way for development of new antimalarial treatments

Malaria remains one of the world's leading causes of mortality in developing countries. Last year alone, it killed more than 400,000 people, mostly young children.

16 Sep 2016

Chemists develop one-step solution to make precursors for synthesis of drugs

A one-step solution to make nitrogen-laden molecular precursors for the preparation of drugs and other bioactive molecules has been discovered by researchers at Rice University, the University of Texas Southwestern Medical Center and Brigham Young University.

13 Sep 2016

NanoTemper Technologies employs game-changing solutions for faster drug development

Following a successful inaugural meeting in 2014, the 2nd Drug Discovery Forum (DDF) took place on May 8–11, 2016 at the Westin Grand Hotel in Munich.

From NanoTemper Technologies 2 Sep 2016

NanoTemper Technologies to highlight applications of MST, nanoDSF in drug discovery at Biopharma Workshop 2016

NanoTemper Technologies offers MicroScale Thermophoresis (MST) and nanoDSF technology to analyze these parameters in an easy and precise way. To meet the increasing demand for high-throughput applications and unattended operation, NanoTemper Technologies provides fully automated MST and nanoDSF platforms — and combinations of both.

From NanoTemper Technologies 2 Sep 2016

New collaborative initiative to develop novel ways of screening drugs for bipolar disorder, schizophrenia

The Johns Hopkins University School of Medicine and the Salk Institute for Biological Studies will co-lead a $15.4 million effort to develop new systems for quickly screening libraries of drugs for potential effectiveness against schizophrenia and bipolar disorder, the National Institute of Mental Health (NIMH) has announced.

2 Sep 2016

Researchers working to find faster way to treat sleeping sickness using oral drugs

Researchers at the University of Georgia are working to find the fastest way possible to treat and cure human African trypanosomiasis, long referred to as sleeping sickness. By working to improve chemical entities already tested in human clinical trials, they hope to have a faster route to field studies to treat the disease using drugs that can be administered orally to patients.

30 Aug 2016

Boehringer Ingelheim and Duke expand collaboration to create largest patient registry for idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.

29 Aug 2016

Drug Discovery News and Research

Further Reading

Women may have better verbal memory skills than men during early stages of Alzheimer's disease

Novel bifunctional dimers show promise in preventing Parkinson's disease

Professor David Goldstein appointed as chief adviser for AstraZeneca’s genomics initiative

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

Experimental PET tracer can diagnose concussion-related brain degeneration in living person

EVG brings high-volume manufacturing process solutions to biotechnology and medical device market

Magnetic bacteria can be promising vehicle for efficiently delivering tumor-fighting drugs

Virginia Tech researchers identify novel compound that blocks growth of deadly fungus

Experts receive $5.2 million NIH grant to develop affordable test for diagnosing Chagas disease

Crick researchers find promising target for new tuberculosis drugs

Human pluripotent stem cells may revolutionize drug discovery in heart disease

Open-source research mechanism could lead to discovery of new, cheap medicines for malaria

Unique open science project shows way for development of new antimalarial treatments

Chemists develop one-step solution to make precursors for synthesis of drugs

NanoTemper Technologies employs game-changing solutions for faster drug development

NanoTemper Technologies to highlight applications of MST, nanoDSF in drug discovery at Biopharma Workshop 2016

New collaborative initiative to develop novel ways of screening drugs for bipolar disorder, schizophrenia

Researchers working to find faster way to treat sleeping sickness using oral drugs

Boehringer Ingelheim and Duke expand collaboration to create largest patient registry for idiopathic pulmonary fibrosis (IPF)

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News